| Literature DB >> 35495374 |
Azita Shishegar1, Matin Vahedi2,3, Fereshteh Kamani2, Mehrdad Fathi Kazerouni3, Morteza Aghajanpour Pasha4, Farhad Fathi2.
Abstract
Partial gastrectomy surgeries are conducted frequently due to various reasons but there is no consensus regarding the method of choice for gastrointestinal reconstruction. In this study we aimed to compare Billroth II with Braun anastomosis and Roux-en-Y gastrojejunostomy. This randomized, Single-blind clinical trial was conducted on patients presented to surgery clinic at Besat and Taleghani hospital between 2018 and 2020 who were gastrectomy candidates. Patients undergoing Billroth II reconstruction with Braun anastomosis or Roux-en-Y gastrojejunostomy were enrolled in the study. Demographics, operation durative and intraoperative blood loss, early postoperative complications, re-admission within 30 days post operation, 30-day and 90-day mortality were recorded. at an at least 3-month post-surgery period, patients were followed for late postoperative complications. If necessary, endoscopy was conducted and biopsy was taken. Analysis was performed with SPSS version 22. A total of 84 patients in two 42-patient groups were evaluated. All parameters were the same in two groups except operation duration and intraoperative bleeding (significantly higher in RY group), food residue (significantly higher in RY group) and bile in remnant stomach (significantly higher in B2B group). These two methods of reconstruction are comparable in terms of postoperative complications and mortality rates. Food residue and bile reflux are two determinants which should be kept in mind when choosing the surgery plan by surgeons. This trial was prospectively registered in the Iranian Registry of Clinical Trials with a registration ID of IRCT20130706013875N3.Entities:
Keywords: Billroth; Braun; Gastrectomy; Reconstruction; Roux en Y anastomosis
Year: 2022 PMID: 35495374 PMCID: PMC9052292 DOI: 10.1016/j.amsu.2022.103544
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Demographics and baseline characteristics in patients of B2B and RY groups.
| Parameter | B2B | RY | p-value |
|---|---|---|---|
| Age (years) | 59.8 ± 12.7 | 57.3 ± 11.8 | 0.299 |
| Gender | |||
Male | 26 (61.9%) | 31 (73.80%) | 0.721 |
Female | 16 (38.09%) | 11 (26.19%) | |
| Preoperative weight (kg) | 62.3 ± 9.9 | 66.4 ± 12.3 | 0.251 |
| Preoperative BMI (kg/m2) | 22.7 ± 2.1 | 23.9 ± 3.3 | 0.339 |
| ASA class | |||
I | 24 (57.14%) | 27 (64.28%) | 0.209 |
II | 18 (42.85%) | 15 (35.71%) | |
| Preoperative albumin (mg) | 3.5 ± 0.4 | 3.6 ± 0.2 | 0.711 |
| Comorbidities | |||
Renal failure | 1 (2.38%) | 1 (2.38%) | 0.961 |
Liver failure | 3 (7.14%) | 1 (2.38%) | 0.127 |
Diabetes mellitus | 8 (19.04%) | 10 (23.80%) | 0.341 |
| Surgery indication | |||
Peptic ulcer | 5 (11.90%) | 6 (14.28%) | 0.347 |
GI bleeding | 8 (19.04%) | 5 (11.90%) | |
Cancer | 29 (69.04%) | 31 (73.80%) | |
Intraoperative parameters in B2B and RY groups.
| Parameter | B2B | RY | p-value |
|---|---|---|---|
| Surgery duration (min) | 141.7 ± 32.9 | 166.3 ± 27.9 | 0.007 |
| Blood loss (ml) | 160.3 ± 52.3 | 252.7 ± 62.9 | 0.021 |
Early postoperative complications in B2B and RY groups.
| Complication | B2B | RY | p-value |
|---|---|---|---|
| Surgical site infection | 2 (4.7%) | 3 (7.14%) | 0.312 |
| Anastomotic leak | 1 (2.3%) | 2 (4.76%) | 0.844 |
| GI bleeding | 2 (4.7%) | 1 (2.3%) | 0.571 |
| Pneumonia | 2 (4.7%) | 3 (7.14%) | 0.568 |
| Deep venous thrombosis | 1 (2.3%) | 1 (2.3%) | 0.471 |
| Renal failure requiring dialysis | 1 (2.3%) | 1 (2.3%) | 0.398 |
| Myocardial infarction | 1 (2.3%) | 1 (2.3%) | 0.254 |
| Adjuant therapy requirement | 22 (52.3%) | 19 (45.2%) | 0.891 |
| Postoperative bleeding | 1 (2.3%) | 1 (2.3%) | 0.254 |
Late postoperative complications in B2B and RY groups.
| Complication | B2B | RY | p-value |
|---|---|---|---|
| Diarrhea | 3 (7.14%) | 4 (9.52%) | 0.209 |
| Dumping syndrome | 2 (4.7%) | 1 (2.3%) | 0.811 |
| Dysphagia | 4 (9.52%) | 3 (7.14%) | 0.742 |
| Odynophagia | 2 (4.7%) | 2 (4.7%) | 0.671 |
| Delayed gastric emptying | 5 (11.9%) | 4 (9.52%) | 0.339 |
| Obstruction symptoms | 2 (4.7%) | 1 (2.3%) | 0.592 |
Endoscopic findings in B2B and RY groups.
| Finding | B2B | RY | p-value |
|---|---|---|---|
| Esophagitis | |||
A | 7 (16.6%) | 6 (14.28%) | 0.254 |
B | 1 (2.3%) | 1 (2.3%) | |
C | 1 (2.3%) | 1 (2.3%) | |
D | 0 (0%) | 0 (0%) | |
| Gastritis | |||
Mild | 8 (19.04%) | 5 (11.90%) | 0.511 |
Moderate | 2 (4.76%) | 2 (4.76%) | |
Severe | 2 (4.76%) | 0 (0%) | |
| Erosion in stomach | 1 (2.3%) | 0 (0%) | 0.594 |
| Mass in stomach | 0 (0%) | 0 (0%) | 1.00 |
| Anastomotic stricture | 1 (2.3%) | 1 (2.3%) | 0.679 |
| Food residue | |||
1 | 0 (0%) | 2 (4.7%) | 0.034 |
2 | 0 (0%) | 2 (4.7%) | |
3 | 0 (0%) | 1 (2.3%) | |
4 | 0 (0%) | 0 (0%) | |
| Bile in stomach | 8 (19.04%) | 1 (2.3%) | 0.012 |
Histopathologic findings in biopsies of patients.
| Finding | B2B | RY | p-value |
|---|---|---|---|
| Chronic inflammation | 9 (21.42%) | 7 (16.66%) | 0.581 |
| Neutrophilic infiltration | 7 (16.66%) | 7 (16.66%) | 0.239 |
| Metaplasia | 1 (2.37%) | 4 (9.52%) | 0.081 |
| Glandular atrophy | 0 (0%) | 0 (0%) | 1.00 |
| 2 (4.7%) | 5 (11.90%) | 0.821 | |
| Dysplasia | 0 (0%) | 0 (0%) | 1.00 |